Norbrook Holdings Ltd today announced its results for the year to 31st July 2017 which show Revenue of £272 million, up 14% year-on-year (CER:5%) and an increase in Operating Profit of £11.7 million to £50.2 million.
2017 was another strong year with growth across the business and significant capital investment made to further strengthen the company’s position in the global veterinary pharmaceutical market.
Liam Nagle, Chief Executive Officer, Norbrook said, “2017 was a solid year for us. We invested significantly in the business with a second new laboratory facility; upgrades to, and expansion of our manufacturing capability; and continued investment in our IT infrastructure. We further strengthened our portfolio with three new products. Carprofen Chewable Tablets for Dogs in the US in particular, supports our business growth plans in this significant market. New product development is a key growth driver for us going forward and we continue to work closely with our Customers to identify new opportunities.
“We are very confident in our plans for the future and our portfolio. We will continue to invest in delivering growth and a sustainable business with a clear and focused strategy to take advantage of what continues to be a buoyant veterinary pharmaceutical sector.”
The company recorded another solid year with growth generated across the business. Turnover increased by £33 million or 14% (CER:5%) to £272 million with Operating Profit of £50.2 million, up £11.7 million.